Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study-Reference-Cited by-同舟云学术

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

Published:2013-07-25 Issue:4 Volume:122 Page:515-522
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Ross David M.¹²³⁴,Branford Susan⁵,Seymour John F.²⁶,Schwarer Anthony P.²⁷,Arthur Christopher²⁸,Yeung David T.¹²³,Dang Phuong¹,Goyne Jarrad M.¹,Slader Cassandra⁹,Filshie Robin J.²¹⁰,Mills Anthony K.²¹¹,Melo Junia V.¹³,White Deborah L.¹²³,Grigg Andrew P.²¹²,Hughes Timothy P.¹²³

Affiliation:

1. Haematology, SA Pathology, Adelaide, Australia;

2. Australasian Leukaemia and Lymphoma Group, Melbourne, Australia;

3. School of Medicine, University of Adelaide, Adelaide, Australia;

4. School of Medicine, Flinders University, Adelaide, Australia;

5. Genetic Pathology, SA Pathology, Adelaide, Australia;

6. Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia;

7. Haematology, The Alfred Hospital, Melbourne, Australia;

8. Haematology, Royal North Shore Hospital, Sydney, Australia;

9. Novartis Oncology, Sydney, Australia;

10. Haematology, St. Vincent’s Hospital, Melbourne, Australia;

11. Haematology, Princess Alexandra Hospital, Brisbane, Australia; and

12. Haematology, Royal Melbourne Hospital and Austin Hospital, Melbourne, Australia

Abstract

Key Points Approximately 40% of patients with undetectable minimal residual disease on imatinib can stop treatment without loss of molecular response. Patients in treatment-free remission still have detectable BCR-ABL DNA several years after stopping imatinib.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/4/515/1372914/515.pdf

Reference37 articles.

1. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.;Hughes;N Engl J Med,2003

2. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.;Hughes;Blood,2006

3. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.;Branford;Clin Cancer Res,2007

4. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.;Baccarani;J Clin Oncol,2009

5. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.;Rousselot;Blood,2007

Cited by 601 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia;Leukemia;2024-02-02

2. Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial;Leukemia;2024-01-26

3. Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease;Nature Communications;2024-01-22

4. 25 years of experience in the treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: results, opportunities, questions;Meditsinskiy sovet = Medical Council;2024-01-17

5. Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript;Annals of Hematology;2024-01-09